{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-395517","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2026-09-18T20:05:31+00:00","discovered_at":"2026-09-18T20:06:00.229749+00:00","generated_at":"2026-09-18T20:06:07.741306+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Karyopharm issues $20M Series A convertible preferred stock to settle forbearance fees","bullets":["Issued 20,000 shares of 0% Series A Convertible Perpetual Preferred, $1,000 liquidation preference each, on Sept 17, 2026.","Convertible into common at $1.62/share; capped at 4,520,000 shares until stockholder consent, with cash settlement for excess.","Preferred ranks senior to common; holders can force repurchase at $1,000 after Sept 17, 2029 or on fundamental changes.","Company must seek stockholder approval by March 15, 2027; deferred cash settlement until then if conversion exceeds cap."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-395517","json":"https://secwatch.observer/filing/0001193125-26-395517.json","markdown":"https://secwatch.observer/filing/0001193125-26-395517.md","text":"https://secwatch.observer/filing/0001193125-26-395517.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526395517/0001193125-26-395517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526395517/d141487d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-18T20:06:07.741306+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}